Aberrant accumulation of b-catenin is closely related to carcinogenesis. Mutations in the p53 gene are reported to induce the aberrant accumulation of b-catenin in the absence of dysfunction in the glycogen synthase kinase 3b (GSK3b)-mediated degradation pathway, but the mechanism remains incompletely understood. Here, we show that human coiled-coil domain containing 85B (CCDC85B) is induced by p53 and regulates b-catenin activity via interaction with the T-cell factor 4 in the nucleus. Moreover, CCDC85B enhances the degradation of b-catenin and suppresses tumor cell growth. In conclusion, we revealed that CCDC85B-induced degradation of b-catenin is independent of GSK3b and other p53-inducible products, Siah-1L, suggesting that CCDC85B constitutes the one of the frameworks of p53-induced multiple regulatory pathways for b-catenin activity.
Introduction
b-Catenin plays a key role in transduction of the Wnt signal by activating target gene expression in complexes with T-cell factor (TCF)/lymphocyte enhancer binding factor (LEF) transcription factors (Willert and Nusse, 1998) . Constitutive activation by b-catenin-TCF/LEF complexes of target genes such as cyclin D1 (Tetsu and McCormick, 1999) and c-myc (He et al., 1998) , which provide growth advantage to cells, is believed to contribute to oncogenesis.
The aberrant accumulation of b-catenin is frequently observed in various human cancers (Chung, 2000; Park et al., 2001 ). The current model suggests that AXIN and adenomatous polyposis coli gene products serve as scaffolds to facilitate the phosphorylation of b-catenin by glycogen synthase kinase 3b (GSK3b; Hart et al., 1998; Henderson, 2000) . Phosphorylated b-catenin is a target for proteasomal degradation. On the other hand, it has been reported that mutations in p53 induce aberrant accumulation of b-catenin in various human cancers and human cell lines without dysfunction of GSK3b-mediated degradation system (Cagatay and Ozturk, 2002; Prange et al., 2003; Harris and Levine, 2005) . Moreover, mutation rates of p53 and b-catenin gene are inversely correlated in patients with hepatocellular carcinoma (Cagatay and Ozturk, 2002) . These data suggest a possible cross talk between b-catenin and p53 signaling pathway. Indeed, we have previously reported that Siah-1L, which is one isoform of Siah-1 and induced by p53, regulates b-catenin independent of the phosphorylation status of b-catenin (Matsuzawa and Reed, 2001; Iwai et al., 2004) . However, the exact mechanism of p53-mediated regulation of b-catenin is not fully clarified. Because p53 enhances expression of various target genes, we hypothesized that a possible mechanism in which other p53-inducible genes might affect b-catenin activity. We demonstrate here that coiled-coil domain containing 85B (CCDC85B), which is a novel p53-inducible molecule, regulates b-catenin activity in a p53-dependent manner. Our findings provide novel insights into the mechanism of b-catenin accumulation in cancers lacking functional p53.
Results

CCDC85B is upregulated by p53
We performed cDNA microarrays to examine the expression profiles of 44 932 genes in Saos-2 cells infected with Ad-p53 (recombinant p53 expression adenovirus vector) or Ad-LacZ (control adenovirus vector containing the bacterial LacZ gene). We found that the relative amount of CCDC85B gene (GenBank no. NM_006848) was increased in Ad-p53-infected Saos-2 cells. The physiological role of CCDC85B is not exactly clear (Brazas and Ganem, 1996) .
To determine whether CCDC85B mRNA expression was actually upregulated by p53, we further investigated the expression of the CCDC85B mRNA in HepG2 cells after treatment with doxorubicin (DOX), which is known to activate p53. As shown in Figure 1a , CCDC85B mRNA was strongly induced 12-24 h after DOX treatment, whereas CCDC85B transcript was barely detectable in the control cells. Moreover, the level of endogenous CCDC85B protein was apparently upregulated at 24 h after DOX treatment, when p53 protein production was strongly induced (Figure 1b) . We then investigated the expression levels of CCDC85B transcripts in Hep3B cells, which have been reported to lack both alleles of p53 (Lee et al., 2002) . As expected, p53 protein production was undetectable in the cells both with and without DOX treatment of the cells (data not shown). Similarly, the CCDC85B mRNA was undetectable in both the presence and absence of DOX ( Figure 1c ). As shown in Figure 1d , increased amounts of CCDC85B gene were found in p53-producing Hep3B cells, but not in control cells. Mutant p53, which has a point mutation in the transactivation domain, did not increase the production of CCDC85B mRNA (Figure 1d ). Similar results were also shown in H1299 and HUH6 cells (Supplementary Figure 1A) . These findings strongly suggest that expression of the CCDC85B gene was specifically induced by p53.
CCDC85B suppresses TCF/LEF-dependent b-catenin activity It has been reported that activated p53 downregulates b-catenin activity (Cagatay and Ozturk, 2002; Prange et al., 2003) . These data prompted us to examine whether CCDC85B production by p53 affects the ability of b-catenin to activate the TCF/LEF-regulated promoter in cells. As shown in Figure 2a , there was about a 70-fold augmentation of relative luciferase activity in HEK293 cells transfected with an expression plasmid encoding b-catenin. When CCDC85B was produced or DOX was treated in HEK293 cells, the levels of TCF/LEF transcriptional activity induced by overproduction of b-catenin were reduced as compared to control cells (Figure 2a ). In contrast, transcription from the reporter plasmid containing the mutated TCF/LEF binding site was not affected by overproduction of b-catenin or CCDC85B proteins. We found a dose-dependent inhibitory effect of CCDC85B on the relative transcriptional activity of TCF/LEF (Supplementary Figure 1B) . b-Catenin is known to be activated by lithium chloride (LiCl) treatment, which inhibits GSK3b activity (Klein and Melton, 1996) . Data showed that CCDC85B and DOX treatment inhibited LiCl-induced signaling (Figure 2b ). Moreover, we examined whether CCDC85B might be responsible for the p53-mediated suppression of b-catenin activity using a short interfering RNA (siRNA) approach. We found siRNAs specific for CCDC85B (siCCDC85B1 or siCCDC85B2) were used to reduce the endogenous levels of CCDC85B; control siRNAs (siCTR1 or siCTR2) had no effect (Supplementary Figure 2A ). The transfection of siCCDC85B recovered the suppression of b-catenin activity induced by DOX (Figure 2b) .
To determine what part of CCDC85B is responsible for the suppression of TCF/LEF transcriptional activity, various mutant forms of the CCDC85B gene were tested using reporter assay. The schematic presentation of the CCDC85B gene and the various mutant forms are shown in Figure 2c . CCDC85B-C2 suppressed luciferase activity when this mutant CCDC85B was co-produced with b-catenin (Figure 2d ). However, in cells co-transfected with the genes for b-catenin and CCDC85B-C1 suppression of TCF/LEF transcriptional activity was not observed (Figure 2d ). To narrow down the region responsible for the suppression of b-catenin activity, we examined the effects of three mutants of the CCDC85B gene: CCDC85B-AA, CCDC85B-L130A and CCDC85B-L131A ( Figure 2c ). As shown in Figure 2d , the TCF/LEF-dependent transcriptional activity did not change in the CCDC85B-AA-or CCDC85B-L131A-transfected cells compared with control cells, whereas the CCDC85B-L130A-transfected cells showed suppressed TCF/LEF activity. These findings were also shown in H1299 and HUH6 cells (Supplementary Figure 1C) .
Cyclin D1 and c-myc are target genes of TCF/LEFb-catenin transcription. Next, we examined the mRNA levels of endogenous cyclin D1 and c-myc using quantitative RT-PCR assay with or without CCDC85B. When CCDC85B and b-catenin was coexpressed in HEK293 cells, both these genes' mRNA levels were markedly suppressed compared to only b-catenin expression (Figure 2e ). In contrast, both target genes' mRNA levels did not change CCDC85B-L131A-expressed cells (Figure 2e ). These findings were also shown in H1299 and HUH6 cells (Supplementary Figure 1D ). These findings suggest that the leucine at position 131 of CCDC85B is involved in its suppressive action on TCF/LEF-dependent b-catenin activity. ). Total RNA was isolated before (0 h) and 12 and 24 h after DOX treatment. RT-PCR assays were performed using specific primers. (b) Total protein was immediately isolated from HepG2 cells before (0 h) and 12 and 24 h after treatment with DOX (15 mg ml
À1
). Endogenous expression levels of CCDC85B were monitored by immunoblotting. (c) Total RNA was isolated sequentially from Hep3B cells (p53 null type) before (0 h) and after DOX treatment (12, 24 h). RT-PCR was performed using specific primers. (d) Hep3B cells were transfected with p53 (p53), mutant p53 (Mut-p53) or empty expression plasmid (CTR). The levels of CCDC85B mRNAs were determined by RT-PCR.
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The b-catenin activity is known to play an important role in tumor cell growth. To explore the functional significance of CCDC85B in tumor cell growth, we examined whether CCDC85B affects the growth of tumor cells using colony formation assay. As shown in Figure 2f , colony number was markedly decreased in the CCDC85B-transfected cells, as in the p53-transfected cells. In contrast, colony number was not changed compared with control cells in CCDC85B-L131A-transfected cells. These results were shown in H1299 and HUH6 cells (Supplementary Figure 1E) . These data suggest that CCDC85B induces the inhibition of tumor cell growth, similar to p53.
CCDC85B enhances the degradation of b-catenin via proteasome system
We investigated the cellular protein levels of b-catenin in the presence or absence of CCDC85B. First, we examined the effects of CCDC85B on endogenous b-catenin levels using HUH6 cells co-transfected with empty vector or CCDC85B expression plasmids together with a plasmid bearing the puromycin-resistance gene expression unit. CCDC85B-expressing cells were concentrated by selective culture in the presence of puromycin. As shown in Figure 3a , there was a marked reduction in the levels of endogenous b-catenin protein in the cells expressing CCDC85B. This CCDC85B-dependent degradation of b-catenin was also observed when b-catenin was expressed ectopically together with CCDC85B ( Figure 3b, left panel) . This reduction in b-catenin protein production was counteracted by the addition of MG132 (proteasome inhibitor; Figure 3b , right panel), implying that the degradation of b-catenin involves proteasome activity.
To determine what part of CCDC85B might be responsible for the degradation of b-catenin, we examined the levels of b-catenin in the cells transfected with the expression plasmids for various mutant forms of CCDC85B. Neither the CCDC85B-AA nor the CCDC85B-L131A expression plasmid-transfected cells showed any degradation of b-catenin, compared with cells producing CCDC85B-L130A similar to control cells (Figure 3c ). To clarify whether CCDC85B might be responsible for the p53-mediated degradation of b-catenin, we examined b-catenin levels with siCCDC85B1, siCCDC85B2, siCTR1, or siCTR2. The p53-induced degradation of b-catenin was almost suppressed by transfection of siCCDC85B1 and 2, but not by siCTR1 and 2 (Figure 3d ). These findings were also shown in H1299 and HUH6 cells (Supplementary Figure 2C) . 
CCDC85B competes with b-catenin for TCF4
A Iwai et al Next, we examined whether degradation of b-catenin by CCDC85B contribute to GSK3b or Siah-1L. As shown in Figure 3e , CCDC85B reduced the levels of b-catenin (AAAA), which has four point mutations (S33A, S37A, T41A and S45A) in the potential GSK3b phosphorylation sites and is resistant to GSK3b-mediated degradation system. Next, we designed specific siRNA for Siah-1L (siSiah-1L; Supplementary Figure  2B) , and demonstrated that CCDC85B reduced the levels of b-catenin in siSiah-1L-treated cells (Figure 3f ).
These findings suggest that CCDC85B induces the degradation of b-catenin via the proteasome system.
CCDC85B interacts with TCF4 in the nucleus
Previous studies showed location of TCF/LEF family and CCDC85B in the nucleus (Brazas and Ganem, 1996; Willert and Nusse, 1998) . These reports suggest that CCDC85B may interact with TCF/LEF family. We examined whether CCDC85B and TCF4, which is a major molecule of the interaction with b-catenin in many human cancers among TCF/LEF family protein (Roose and Clevers, 1999) , were co-localized. Immunofluorescence analyses showed that similar to TCF4, CCDC85B protein is localized mainly in the nuclei (Figure 4a ). We then used glutathione s-transferase (GST) pull-down assay to test whether CCDC85B interacts with TCF4. The [ CCDC85B competes with b-catenin for TCF4 A Iwai et al was showed specific association with a recombinant CCDC85B fused with GST (GST-CCDC85B), but not with GST itself (Figure 4b ). Furthermore, we found that endogenous CCDC85B was interacted with endogenous TCF4 using immunoprecipitation assay (Figure 4c ). This finding was also observed in HUH6 and AGS cells (Supplementary Figure 3A) . Next, we observed that TCF4 co-immunoprecipitated with CCDC85B from the lysates of the cells producing both exogenous CCDC85B and TCF4 (Figure 4d, upper panel) . In contrast, CCDC85B-L131A, which did not affect the b-catenindependent transcriptional activity, did not interact with TCF4 (Figure 4d, lower panel) . These findings suggest that CCDC85B might interact with TCF4 via the leucine at position 131 of CCDC85B in the nucleus.
CCDC85B inhibits the interaction between b-catenin and TCF4
The TCF4 contains an N-terminal b-catenin binding domain (bBD) and a sequence-specific DNA binding region called the HMG box (HMG) (Hurlstone and Clevers, 2002) . To decide what part of TCF4 plays a role in the interaction with CCDC85B, we investigated the interaction of CCDC85B with the various mutant forms of TCF4 as shown in Figure 5a . As shown in Figure 5b (middle panel), we found that CCDC85B interacted with TCF4 (327-596). In contrast, TCF4 (1-326) and TCF4 (400-596) did not interact with CCDC85B protein (Figure 5b ; upper and lower panel). Thus, CCDC85B interacts with TCF4 via a different region of b-catenin binding domain in TCF4. These findings suggest that the HMG box of TCF4 is a key region in interaction of these proteins.
Both b-catenin and CCDC85B interacted with TCF4 prompted us to examine whether CCDC85B competes with b-catenin for interacting with TCF4. We designed a competition assay to assess the binding of b-catenin to TCF4 in the presence of varying amounts of CCDC85B or CCDC85B-L131A. Cells were transfected with fixed amounts of Flag-TCF4 and Myc-b-catenin, and increasing amounts of HA-CCDC85B or -CCDC85B-L131A expression vectors. The b-catenin and TCF4 interactions were monitored by immunoprecipitation-coupled immunoblotting analyses in the presence of proteasome inhibitors. As shown in left panel of Figure 5c , production of CCDC85B reduced the interaction of b-catenin with TCF4 in a dose-dependent manner. When we performed a competition assay using the expression plasmid CCDC85B-L131A, an inactive mutant, the interaction of b-catenin with TCF4 was unaffected (Figure 5c , right panel). These finding were also observed in H1299 and HUH6 cells (Supplementary Figure 3B and C) . Next, we examined the localization of b-catenin with or without CCDC85B in LiCl and MG132-treated cells. The nuclear accumulation of b-catenin is shown in these cells (Klein and Melton, 1996) . In CCDC85B-transfected cells, bcatenin was almost not localized in nuclear (Figure 5d ). In contrast, b-catenin was mainly localized in nuclear, when CCDC85B-L131A overproducing cells (Figure 5d ). These findings suggest that the suppression of b-catenin activity by CCDC85B is invoked by disassociation of b-catenin from the TCF4 via a competitive interaction with CCDC85B.
Discussion
In this study, we demonstrated that the expression of CCDC85B is regulated in a p53-dependent manner. We also showed that CCDC85B has an inhibitory role in b-catenin activity through interaction with the TCF4. 
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It has been suggested that CCDC85B may act as a downstream effector of p53. The 5 0 -flanking region of CCDC85B lacks the typical TATA box or CCATT box. The 2244 bp DNA fragment of the 5 0 -franking region was subcloned into reporter plasmid, however this fragment did not response to p53 (data not shown). Further investigation will be required to clarify the mechanisms of expression of the CCDC85B gene.
It has been reported that aberrant accumulation of b-catenin in cancers often associated with inactivation of p53 (Sadot et al., 2001; Cagatay and Ozturk, 2002) . In this regard, p53-inducible gene PTEN (Stambolic et al., 2001) or Siah-1L (Matsuzawa and Reed, 2001; Iwai et al., 2004) reduces cellular levels of b-catenin. Absence of PTEN protein suppresses the phosphorylation of b-catenin via inactivation of GSK3b. We demonstrated here that CCDC85B is able to regulate the levels of b-catenin independent of GSK3b-mediated degradation system. The Siah-family proteins, including Siah-1L, target b-catenin protein for degradation regardless of b-catenin phosphorylation (Matsuzawa and Reed, 2001; Iwai et al., 2004) . However, we demonstrated that knock down of Siah-1L by siRNA treatment did not affect the inhibitory effect of CCDC85B on b-catenin. These results indicate that the regulation of b-catenin via the CCDC85B pathway dose not involve GSK3b and Siah-1L pathway.
We demonstrated that interaction between CCDC85B and TCF4 protein was important for regulating the levels of b-catenin. However, the molecular mechanism of how CCDC85B reduces b-catenin levels through interaction with the TCF4 is not clear. It is known that b-catenin shuttles between the cytoplasm and the nucleus (Henderson, 2000) . The TCF/LEF family of proteins might serve to anchor nuclear b-catenin to DNA (Tolwinski and Wieschaus, 2001) . Previous study reported that the degradation of b-catenin was stimulated when its interaction with TCF/LEF family of proteins was blocked . Thus, one possibility is that free b-catenin, which is removed from the TCF/LEF family of proteins by CCDC85B, moved to the cytoplasm and is subsequentially degraded by proteasome system. Further study is necessary to clarify the exact molecular mechanism by which b-catenin is degraded by CCDC85B.
In conclusion, p53-dependent production of CCDC85B plays an important role in the regulation of b-catenin activity via competition with the interaction of b-catenin with the TCF4 in the nucleus of human tumor cells. These findings add a novel anti-oncogenic action of p53, namely, blocking b-catenin-dependent gene expression in the nucleus.
Materials and methods
Plasmids
Human CCDC85B, CCDC85B mutants, TCF4 and various TCF4 mutants were constructed by reverse transcription (RT)-PCR assay. These were subcloned into the EcoRI and XhoI sites of the pcDNA3-Flag, pcDNA3-Myc and pcDNA3-HA plasmids. The plasmids pRC-CMV-p53 (wild type), pRC-CMVp53 (179Mut), pcDNA3-Myc-b-catenin, pcDNA3-Myc-b-catenin (AAAA) and pTcf7wt-Luc and pTcf7mut-Luc are described (Iwai et al., 2004) . All constructs were confirmed by DNA sequencing.
Cell culture and transfection Human hepatoma HepG2, HUH6, Hep3B, colon cancer SW48 and human embryonic kidney HEK293 cells were maintained as described previously (Iwai et al., 2004) . The transfection of plasmids into the cells is described previously (Iwai et al., 2004) .
Preparation of RNA and RT-PCR Total Preparation of RNA is described previously (Iwai et al., 2004) . The PCR primers for amplification of CCDC85B were as follows: CCDC85B-53S, 5
0 -CGCTAGGCAAGGAAGAG CTA-3 0 and CCDC85B-419AS, 5 0 -GCTCCTTAAGCGCTA GGTTC-3 0 . The PCR primer for amplification of the genes for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and RT-PCR method are described previously (Iwai et al., 2004) .
Immunoprecipitation assay Immunoprecipitation assay is described previously (Watashi et al., 2003) .
Antibodies
Polyclonal antisera were generated in rabbits using purified recombinant KLH-conjugated CCDC85B (SERQRGRRAAR QWQL; aa 86-100) as an immunogen at Tanpakuseisei Company in Japan. Mouse monoclonal antibodies against b-catenin, p53, c-Myc, Flag, HA and a-actin were prepared as described (Iwai et al., 2004) . Mouse monoclonal anti-TCF4 (6H5-3) was used (Upstate, Lake Placid, NY, USA).
Reporter assay
Reporter assay was performed essentially as described previously (Iwai et al., 2004) .
siRNA technique
We designed the following siRNA duplexes within the open reading frame of CCDC85B to knock down CCDC85B. The siRNA duplexes were synthesized and purified by Invitrogen (San Diego, CA, USA). The CCDC85B gene target sequence were as follows: siCCDC85B1, 5 0 -GACGGACGAGGAGAU GGCGGCGCUA-3 0 and siCCDC85B2, 5 0 -GAAAUCCU GACACCAAGAA-3 0 . The nonsilencing siRNAs (control siRNAs) were as follows: siCTR1, 5 0 -GACGCAGGAAGAG GUGGCGCGGCUA-3 0 and siCTR2, 5 0 -AAGAGCCGUCA GACUGCUACA-3 0 . The siSiah-1L and control siRNA for Siah-1L (siCTR) and siRNA transfection are described previously (Iwai et al., 2004) .
Immunoblotting assay
Immunoblot assay was performed as described previously (Iwai et al., 2004) .
Quantitative RT-PCR assay Quantitative RT-PCR was performed using the SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit with ROX (Invitrogen) according to the manufacturer's protocol. The PCR primer sets for amplification of cyclin D1 and c-myc were as follows: cyclin D1-S, 5 0 -GCAAATGGAGCTGCTCCTG-3 0 and cyclin D1-AS, 5 0 -GCGTGTTTGCGGATGATCTG-3 0 , and c-myc-S, 5 0 -GAACACACAACGTCTTGGAG-3 0 and c-myc-AS, 5 0 -CGGACAGGATGTATGCTGTG-3 0 . The mRNA levels of target genes were normalized to the endogenous CCDC85B competes with b-catenin for TCF4 A Iwai et al mRNA levels of the housekeeping reference gene GAPDH. The relative mRNA levels were presented as mean±s.d. from at least three independent experiments.
Immunofluorescence assay
Immunofluorescence assay was performed as described previously (Watashi et al., 2003) . Signals were detected using confocal microscopy (Leica Microsystems, Wetzlar, Germany).
GST pull-down assay GST-pull-down assay was previously described (Watashi et al., 2003) .
Colony formation assay
Colony formation assay was performed as described previously (Watashi et al., 2003) .
Abbreviations CCDC85B, coiled-coil domain containing 85B; DOX, doxorubicin; GSK3b, glycogen synthase kinase 3b; LEF, lymphocyte enhancer binding factor; LiCl, lithium chloride; siRNA, short interfering RNA; TCF, T-cell factor.
